Literature DB >> 20590585

Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in rats.

N Vanattou-Saïfoudine1, R McNamara, A Harkin.   

Abstract

BACKGROUND AND
PURPOSE: Caffeine exacerbates the hyperthermia associated with an acute exposure to 3,4 methylenedioxymethamphetamine (MDMA, 'Ecstasy') in rats. The present study investigated the mechanisms mediating this interaction. EXPERIMENTAL APPROACH: Adult male Sprague-Dawley rats were treated with caffeine (10 mg x kg(-1); i.p.) and MDMA (15 mg x kg(-1); i.p.) alone and in combination. Core body temperatures were monitored before and after drug administration. KEY
RESULTS: Central catecholamine depletion blocked MDMA-induced hyperthermia and its exacerbation by caffeine. Caffeine provoked a hyperthermic response when the catecholamine releaser d-amphetamine (1 mg x kg(-1)) was combined with the 5-HT releaser D-fenfluramine (5 mg x kg(-1)) or the non-selective dopamine receptor agonist apomorphine (1 mg x kg(-1)) was combined with the 5-HT(2) receptor agonist DOI (2 mg x kg(-1)) but not following either agents alone. Pretreatment with the dopamine D(1) receptor antagonist Schering (SCH) 23390 (1 mg x kg(-1)), the 5-HT(2) receptor antagonist ketanserin (5 mg x kg(-1)) or alpha(1)-adreno- receptor antagonist prazosin (0.2 mg x kg(-1)) blocked MDMA-induced hyperthermia and its exacerbation by caffeine. Co-administration of a combination of MDMA with the PDE-4 inhibitor rolipram (0.025 mg x kg(-1)) and the adenosine A(1/2) receptor antagonist 9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-C]quinazolin-5-amine 15943 (10 mg x kg(-1)) or the A(2A) receptor antagonist SCH 58261 (2 mg x kg(-1)) but not the A(1) receptor antagonist DPCPX (10 mg x kg(-1)) exacerbated MDMA-induced hyperthermia. CONCLUSIONS AND IMPLICATIONS: A mechanism comprising 5-HT and catecholamines is proposed to mediate MDMA-induced hyperthermia. A combination of adenosine A(2A) receptor antagonism and PDE inhibition can account for the exacerbation of MDMA-induced hyperthermia by caffeine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590585      PMCID: PMC2935994          DOI: 10.1111/j.1476-5381.2010.00660.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  75 in total

1.  Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug.

Authors:  Jordi Camarasa; David Pubill; Elena Escubedo
Journal:  Brain Res       Date:  2006-08-02       Impact factor: 3.252

Review 2.  Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain.

Authors:  Sergi Ferre; Francisco Ciruela; Janusz Borycz; Marcello Solinas; Davide Quarta; Katerina Antoniou; Cesar Quiroz; Zuzana Justinova; Carme Lluis; Rafael Franco; Steven R Goldberg
Journal:  Front Biosci       Date:  2008-01-01

Review 3.  An update on the mechanisms of the psychostimulant effects of caffeine.

Authors:  Sergi Ferré
Journal:  J Neurochem       Date:  2007-12-18       Impact factor: 5.372

Review 4.  Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition.

Authors:  T Müller; P Engels; J R Fozard
Journal:  Trends Pharmacol Sci       Date:  1996-08       Impact factor: 14.819

5.  Caffeine induces a profound and persistent tachycardia in response to MDMA ("Ecstasy") administration.

Authors:  Ruth McNamara; Mark Maginn; Andrew Harkin
Journal:  Eur J Pharmacol       Date:  2006-11-03       Impact factor: 4.432

6.  Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum.

Authors:  M Okada; K Mizuno; S Kaneko
Journal:  Neurosci Lett       Date:  1996-07-05       Impact factor: 3.046

7.  Relative contribution of rat cytochrome P450 isoforms to the metabolism of caffeine: the pathway and concentration dependence.

Authors:  Marta Kot; Władysława A Daniel
Journal:  Biochem Pharmacol       Date:  2008-01-05       Impact factor: 5.858

Review 8.  MDMA (Ecstasy).

Authors:  Rif S El-Mallakh; Henry David Abraham
Journal:  Ann Clin Psychiatry       Date:  2007 Jan-Mar       Impact factor: 1.567

9.  Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro.

Authors:  Stéphane Doly; Emmanuel Valjent; Vincent Setola; Jacques Callebert; Denis Hervé; Jean-Marie Launay; Luc Maroteaux
Journal:  J Neurosci       Date:  2008-03-12       Impact factor: 6.167

10.  Serotonin depletion decreases serotonin transporter mRNA levels in rat brain.

Authors:  K Linnet; K Koed; O Wiborg; N Gregersen
Journal:  Brain Res       Date:  1995-10-30       Impact factor: 3.252

View more
  10 in total

1.  'Ecstasy' enhances noise-induced hearing loss.

Authors:  Michael W Church; Jinsheng S Zhang; Megan M Langford; Shane A Perrine
Journal:  Hear Res       Date:  2013-05-25       Impact factor: 3.208

2.  Caffeine promotes dopamine D1 receptor-mediated body temperature, heart rate and behavioural responses to MDMA ('ecstasy').

Authors:  Natacha Vanattou-Saïfoudine; Ruth McNamara; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2010-05-02       Impact factor: 4.530

3.  D1 but not D4 dopamine receptors are critical for MDMA-induced neurotoxicity in mice.

Authors:  N Granado; S Ares-Santos; R Moratalla
Journal:  Neurotox Res       Date:  2013-11-21       Impact factor: 3.911

Review 4.  Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediators.

Authors:  N Vanattou-Saïfoudine; R McNamara; A Harkin
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

5.  Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia.

Authors:  S E Shortall; A R Green; K M Swift; K C F Fone; M V King
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  Influence of chronic caffeine on MDMA-induced behavioral and neuroinflammatory response in mice.

Authors:  Jessica Ruiz-Medina; Ana Pinto-Xavier; Marta Rodríguez-Arias; José Miñarro; Olga Valverde
Journal:  Psychopharmacology (Berl)       Date:  2012-11-29       Impact factor: 4.530

7.  Inhibition of the dorsomedial hypothalamus, but not the medullary raphe pallidus, decreases hyperthermia and mortality from MDMA given in a warm environment.

Authors:  Dmitry V Zaretsky; Maria V Zaretskaia; Pamela J Durant; Daniel E Rusyniak
Journal:  Pharmacol Res Perspect       Date:  2014-04-01

8.  The role of adenosine A1 and A2A receptors in the caffeine effect on MDMA-induced DA and 5-HT release in the mouse striatum.

Authors:  A M Górska; K Gołembiowska
Journal:  Neurotox Res       Date:  2014-11-13       Impact factor: 3.911

9.  Neurochemical and Neurotoxic Effects of MDMA (Ecstasy) and Caffeine After Chronic Combined Administration in Mice.

Authors:  Anna Maria Górska; Katarzyna Kamińska; Agnieszka Wawrzczak-Bargieła; Giulia Costa; Micaela Morelli; Ryszard Przewłocki; Grzegorz Kreiner; Krystyna Gołembiowska
Journal:  Neurotox Res       Date:  2017-11-13       Impact factor: 3.911

Review 10.  The Role of Adenosine Receptors in Psychostimulant Addiction.

Authors:  Inmaculada Ballesteros-Yáñez; Carlos A Castillo; Stefania Merighi; Stefania Gessi
Journal:  Front Pharmacol       Date:  2018-01-10       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.